Detailed View
XERS - Xeris Biopharma Holdings, Inc.
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
1,436,381,824
Adj EBIT (TTM)
53,853,000
Enterprise Value
1,545,855,824
Last Price
8.32
Earnings Yield
3.48%
Return on Capital
32.60%
Capital
165,193,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 83,127,000 | 7,916,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 85,807,000 | 16,773,000 |
| 2025-09-30 | 10-Q | 2025 | 74,380,000 | 6,731,000 |
| 2025-06-30 | 10-Q | 2025 | 71,539,000 | 4,482,000 |
| 2025-03-31 | 10-Q | 2025 | 60,119,000 | -3,090,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 60,099,000 | 1,679,000 |
| 2024-09-30 | 10-Q | 2024 | 54,268,000 | -12,893,000 |
| 2024-06-30 | 10-Q | 2024 | 48,065,000 | -8,187,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.